ArticleMolecular medicine reports2026
Sleep deprivation exacerbates lens‑induced myopia in association with ERK/NF‑κB pathway activation.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study was to examine the molecular mechanisms by which sleep deprivation (SD) exacerbates lens‑induced myopia (LIM). Guinea pig models were established for the LIM and LIM + SD groups, with 15 animals per group. Guinea pigs in the LIM + SD group underwent 20 h of daily SD in addition to wearing concave lenses on the right eye. Additional guinea pig models were established for the LIM + SD and LIM + SD + BVD‑523 groups, each containing 15 animals. The LIM + SD + BVD‑523 group received oral administration of BVD‑523, an inhibitor of the ERK1/2. Biological parameters, including diopter and axial length, were measured. Retinal dopamine (DA) levels were evaluated with high‑performance liquid chromatography-electrochemistry, tyrosine hydroxylase (TH) expression by immunofluorescence staining, retinal ERK/NF‑κB signaling pathway expression by western blotting and retinal inflammatory cytokine levels by ELISA. Relative to the LIM group, the LIM + SD group demonstrated increased diopter and axial length, decreased retinal DA and TH levels, elevated inflammatory cytokine expression and activation of the ERK/NF‑κB signaling pathway, which were associated with myopia progression. However, administration of BVD‑523 inhibited increases in diopter and axial length, restored retinal DA and TH levels and downregulated inflammatory cytokine expression, which was associated with alleviation of myopia. In conclusion, SD may exacerbate LIM in association with ERK/NF‑κB pathway activation, representing a potential therapeutic target for myopia, as the ERK1/2 inhibitor BVD‑523 can suppress SD‑induced myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.